WuXi Biologics (Cayman)'s latest marketcap:
As of 07/16/2025, WuXi Biologics (Cayman)'s market capitalization has reached $14.15 B. According to our data, WuXi Biologics (Cayman) is the 1448th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 14.15 B |
| Revenue (ttm) | 2.53 B |
| Net Income (ttm) | 454.97 M |
| Shares Out | 4.07 B |
| EPS (ttm) | 0.11 |
| Forward PE | 22.74 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/20/2025 |
WuXi Biologics (Cayman)'s yearly market capitalization.
| Date | Market Cap(HK$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/16/2025 | HK$111.09 B | $14.15 B | 50.97% | 1448 |
| 12/31/2024 | HK$72.1 B | $9.28 B | -42.32% | 1822 |
| 12/29/2023 | HK$124.99 B | $16 B | -50.53% | 1095 |
| 12/30/2022 | HK$252.68 B | $32.34 B | -35.37% | 510 |
| 12/31/2021 | HK$390.94 B | $50.13 B | -6.9% | 381 |
| 12/31/2020 | HK$419.91 B | $54.14 B | 228.82% | 287 |
| 12/31/2019 | HK$127.7 B | $16.39 B | 107.71% | 858 |
| 12/31/2018 | HK$61.48 B | $7.85 B | 20.96% | 1414 |
| 12/29/2017 | HK$50.83 B | $6.5 B | 1900 |
Company Profile
About WuXi Biologics (Cayman) Inc.
WuXi Biologics (Cayman) Inc. is an investment holding company that delivers end-to-end solutions for biologics discovery, development, and manufacturing. Serving global markets, including China, North America, Europe, and Asia-Pacific, the company operates through two key segments: Biologics and XDC.
Core Services & Solutions
- Comprehensive biologics discovery, from concept to IND (Investigational New Drug).
- Contract research, development, and manufacturing (CRDMO) services.
- Proprietary platforms including WuXiBody, SDArBodY, T cell engager, and Single B Cell Cloning Technology.
- Process development, CMC (Chemistry, Manufacturing, and Controls), and downstream solutions.
- Vaccine CDMO services and related business operations.
Additional Offerings
- Biopharmaceutical technology consultation.
- Testing and development of diagnostic technologies.
- Sales, marketing, and clinical manufacturing services.
- Production and distribution of medical products.
- Investment and material supplier activities.
Strategic Partnerships
The company collaborates with leading biotech firms, including a research service agreement with BioNTech SE to develop next-generation monoclonal antibody therapeutics.
Company Background
Founded in 2014, WuXi Biologics is headquartered in Wuxi, China, and has established itself as a key player in the global biologics industry.
Frequently Asked Questions
-
What is WuXi Biologics (Cayman)'s (HKG-2269) current market cap?As of 07/16/2025, WuXi Biologics (Cayman) (including the parent company, if applicable) has an estimated market capitalization of $14.15 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does WuXi Biologics (Cayman) (HKG-2269) rank globally by market cap?WuXi Biologics (Cayman) global market capitalization ranking is approximately 1448 as of 07/16/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.